Opinion|Videos|November 27, 2024
Patient Selection and Personalized Treatment Strategies
Key Takeaways
- Transitioning from IV to oral medications requires careful management of adherence, side effects, and therapeutic efficacy to ensure optimal patient outcomes.
- Patient-specific factors, such as comorbidities and drug interactions, are critical in optimizing treatment during the transition from IV to oral medications.
An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What challenges may exist when transitioning from IV to oral medications?
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5